AC Immune Beheer
Beheer criteriumcontroles 2/4
De CEO AC Immune is Andrea Pfeifer, benoemd in Apr2003, heeft een ambtstermijn van 21.58 jaar. De totale jaarlijkse vergoeding van { bedraagt CHF 2.65M, bestaande uit 21.8% salaris en 78.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.45% van de aandelen van het bedrijf, ter waarde $ 7.26M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 6.6 jaar.
Belangrijke informatie
Andrea Pfeifer
Algemeen directeur
CHF 2.7m
Totale compensatie
Percentage CEO-salaris | 21.8% |
Dienstverband CEO | 21.6yrs |
Eigendom CEO | 2.4% |
Management gemiddelde ambtstermijn | 5.8yrs |
Gemiddelde ambtstermijn bestuur | 6.6yrs |
Recente managementupdates
Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -CHF 61m |
Mar 31 2024 | n/a | n/a | -CHF 55m |
Dec 31 2023 | CHF 3m | CHF 578k | -CHF 54m |
Sep 30 2023 | n/a | n/a | -CHF 68m |
Jun 30 2023 | n/a | n/a | -CHF 67m |
Mar 31 2023 | n/a | n/a | -CHF 69m |
Dec 31 2022 | CHF 2m | CHF 558k | -CHF 71m |
Sep 30 2022 | n/a | n/a | -CHF 73m |
Jun 30 2022 | n/a | n/a | -CHF 76m |
Mar 31 2022 | n/a | n/a | -CHF 75m |
Dec 31 2021 | CHF 2m | CHF 530k | -CHF 73m |
Sep 30 2021 | n/a | n/a | -CHF 71m |
Jun 30 2021 | n/a | n/a | -CHF 74m |
Mar 31 2021 | n/a | n/a | -CHF 71m |
Dec 31 2020 | CHF 2m | CHF 520k | -CHF 62m |
Sep 30 2020 | n/a | n/a | -CHF 62m |
Jun 30 2020 | n/a | n/a | -CHF 25m |
Mar 31 2020 | n/a | n/a | -CHF 26m |
Dec 31 2019 | CHF 2m | CHF 510k | CHF 45m |
Sep 30 2019 | n/a | n/a | CHF 50m |
Jun 30 2019 | n/a | n/a | CHF 18m |
Mar 31 2019 | n/a | n/a | CHF 24m |
Dec 31 2018 | CHF 2m | CHF 455k | -CHF 51m |
Sep 30 2018 | n/a | n/a | -CHF 32m |
Jun 30 2018 | n/a | n/a | -CHF 27m |
Mar 31 2018 | n/a | n/a | -CHF 29m |
Dec 31 2017 | CHF 2m | CHF 404k | -CHF 26m |
Compensatie versus markt: De totale vergoeding ($USD 3.07M ) Andrea } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.48M ).
Compensatie versus inkomsten: De vergoeding van Andrea is gestegen terwijl het bedrijf verliesgevend is.
CEO
Andrea Pfeifer (67 yo)
21.6yrs
Tenure
CHF 2,650,000
Compensatie
Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 21.6yrs | CHF 2.65m | 2.45% $ 7.3m | |
CFO & VP of Finance | 2.6yrs | geen gegevens | 0.013% $ 37.8k | |
Chief Technical Operations Officer | 5.8yrs | geen gegevens | 0.025% $ 73.6k | |
Chief Administrative Officer | 9.3yrs | geen gegevens | 0.32% $ 935.8k | |
Chief HR Officer | 2.6yrs | geen gegevens | 0.020% $ 60.4k | |
Chief Scientific Officer | less than a year | geen gegevens | 0.0032% $ 9.5k | |
Senior VP of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens | |
General Counsel | no data | geen gegevens | geen gegevens | |
VP of U.S. Finance & Corporate Development | 2.6yrs | geen gegevens | geen gegevens | |
Head of AD - SME | 14.8yrs | geen gegevens | geen gegevens | |
Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer | 8.8yrs | geen gegevens | geen gegevens | |
VP & Head of Clinical Development | no data | geen gegevens | geen gegevens |
5.8yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ACIU is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 8.5yrs | CHF 2.65m | 2.45% $ 7.3m | |
Chairman of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Non-Executive Chairman | 6.6yrs | CHF 179.00k | 0.039% $ 116.8k | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | CHF 5.00k | geen gegevens | |
Member of Scientific Advisory Board | no data | CHF 105.00k | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Vice Chair | 3.1yrs | CHF 163.00k | 0.0092% $ 27.5k | |
Head of Clinical Advisory Board | no data | geen gegevens | geen gegevens |
6.6yrs
Gemiddelde duur
74.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ACIU wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.6 jaar).